In this instalment of our clinical trials round-ups, we look at life sciences research and development announced during the week of 3rd to 7th June, from early-stage onwards.
UK start-up Quell Therapeutics has secured a partnership with AstraZeneca focused on cell therapies for autoimmune diseases, with an $85 million upfront payment and which
MSD has been rumoured to be considering a takeover of Viking Therapeutics in order to get a horse in the obesity therapy race but chose instead to back a runner from China's Hansh Pharma.